3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
25
Lymphoma
21
Neutropenia
13
Lymphoma, Large B-Cell, Diffuse
12
Lymphoma, Non-Hodgkin
11
Neoplasms
10
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Carcinoma, Non-Small-Cell Lung
8
Multiple Myeloma
7
Leukemia
7
Burkitt Lymphoma
7
Ovarian Neoplasms
6
Lymphoma, Follicular
6
Lung Neoplasms
5
Leukemia, Lymphocytic, Chronic, B-Cell
5
Urinary Bladder Neoplasms
4
Testicular Neoplasms
4
Sarcoma
4
Lymphoma, Mantle-Cell
4
Lymphoma, Large-Cell, Immunoblastic
4
Lymphoma, B-Cell, Marginal Zone
4
Hodgkin Disease
4
Central Nervous System Neoplasms
4
Testicular Germ Cell Tumor
3
Teratoma
3
Rhabdomyosarcoma
3
Chemotherapy-induced Neutropenia
3
Carcinoma, Ovarian Epithelial
3
Carcinoma, Embryonal
3
Adenocarcinoma, Bronchiolo-Alveolar
3
Interventions
Cisplatin
8
Etoposide
6
Paclitaxel
5
Ifosfamide
4
Sunitinib
3
Oxaliplatin
3
Cyclophosphamide
3
Brentuximab Vedotin
3
tremelimumab
2
pembrolizumab
2
etoposide phosphate
2
durvalumab
2
Sirolimus
2
Gemcitabine
2
Everolimus
2
Epirubicin
2
Dexamethasone
2
Carboplatin
2
Bleomycin
2
Bevacizumab
2
tozuleristide
1
rolapitant
1
ribociclib
1
pegfilgrastim
1
pazopanib
1
olaparib
1
fosaprepitant
1
fludarabine phosphate
1
fludarabine
1
cabozantinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Neoplasms, Germ Cell and Embryonal
×
pegfilgrastim
×
Clear all
NCT06309732
2024-03-13
GAMEC-II
Queen Mary University of London
Phase 2
Completed
36 enrolled